Literature DB >> 23797132

Multimodal treatment strategies in patients undergoing surgery for hepatocellular carcinoma.

Georg Lurje1, Mickaël Lesurtel, Pierre-Alain Clavien.   

Abstract

Hepatocellular carcinoma (HCC) is one of the major health problems worldwide, and continues to grow because of its association with hepatitis B and C viruses. In patients with HCC, liver transplantation (LT) and liver resection are the only two curative treatment options. LT remains the best option since it not only removes the tumor, but also the underlying disease. The prerequisite for long-term success of LT for HCC depends on the tumor load and strict selection criteria with regard to the size and number of existing HCC lesions. The need to obtain the optimal benefit from a limited number of grafts has prompted the implementation of well-defined selection criteria that identify patients with early HCC who may benefit from better long-term outcome after LT. Unfortunately, LT can only be proposed in approximately 30% of patients with HCC due to limitations in donor graft availability. In this particular setting, open and laparoscopic surgical resection represent reasonable treatment modalities in noncirrhotic HCC patients. The decision-making process for liver resection should integrate the tumor stage, quality and function of the underlying liver parenchyma, volume of the future liver remnant, and general condition of the patient. In patients with favorable features (solitary tumor, compensated Child-Pugh A cirrhosis, no portal hypertension), the reported 5-year survival rates range between 50 and 70%. In specific cases, liver resection and LT may be combined in the same patient.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23797132     DOI: 10.1159/000347205

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  7 in total

1.  Prognostic factors of disease-free and overall survival in patients with hepatocellular carcinoma undergoing partial hepatectomy in curative intent.

Authors:  Georg Lurje; Jan Bednarsch; Zoltan Czigany; Iakovos Amygdalos; Franziska Meister; Wenzel Schöning; Tom Florian Ulmer; Martin Foerster; Cornelis Dejong; Ulf Peter Neumann
Journal:  Langenbecks Arch Surg       Date:  2018-09-28       Impact factor: 3.445

2.  Laparoscopic hepatectomy versus radiofrequency ablation for minimally invasive treatment of single, small hepatocellular carcinomas.

Authors:  Juxian Song; Yu Wang; Kuansheng Ma; Shuguo Zheng; Ping Bie; Feng Xia; Xiaowu Li; Jianwei Li; Xiaojun Wang; Jian Chen
Journal:  Surg Endosc       Date:  2015-12-29       Impact factor: 4.584

Review 3.  Anti-cancer properties of specific Chinese herbal medicines for hepatocellular carcinoma treatment.

Authors:  Zang Ping; Xue Jun; Wang Yan; Zhang Jun
Journal:  Eur J Integr Med       Date:  2020-10-03       Impact factor: 1.314

4.  Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma.

Authors:  Edith Y Ho; Myrna L Cozen; Hui Shen; Robert Lerrigo; Erica Trimble; James C Ryan; Carlos U Corvera; Alexander Monto
Journal:  HPB (Oxford)       Date:  2014-01-28       Impact factor: 3.647

5.  The comparison of oncologic and clinical outcomes of laparoscopic liver resection for hepatocellular carcinoma.

Authors:  Sung-Jin Kim; Hwa-Kyung Jung; Dong-Shik Lee; Sung-Su Yun; Hong-Jin Kim
Journal:  Ann Surg Treat Res       Date:  2014-01-22       Impact factor: 1.859

6.  Low‑intensity ultrasound enhances the antitumor effects of doxorubicin on hepatocellular carcinoma cells through the ROS‑miR‑21‑PTEN axis.

Authors:  Chunhua Xia; Huabei Zeng; Yanfen Zheng
Journal:  Mol Med Rep       Date:  2020-01-13       Impact factor: 2.952

7.  Intraoperative Transfusion of Fresh Frozen Plasma Predicts Morbidity Following Partial Liver Resection for Hepatocellular Carcinoma.

Authors:  Jan Bednarsch; Zoltan Czigany; Isabella Lurje; Christian Trautwein; Tom Lüdde; Pavel Strnad; Nadine Therese Gaisa; Alexandra Barabasch; Philipp Bruners; Tom Ulmer; Sven Arke Lang; Ulf Peter Neumann; Georg Lurje
Journal:  J Gastrointest Surg       Date:  2020-06-03       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.